Entities Overview

Path: `entities/overview`

Introduction

The Entities section serves as a comprehensive reference for key biological entities, drug targets, biomarkers, and therapeutic concepts in neurodegenerative disease research. This overview provides context for navigating the 171+ entity pages in NeuroWiki, covering the molecular players, cellular components, and therapeutic interventions central to understanding Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders.

Neurodegenerative diseases share common pathological mechanisms including protein aggregation, mitochondrial dysfunction, neuroinflammation, and impaired protein homeostasis. The entities documented in this section represent the key molecular actors in these processes, spanning from disease-causing genes and aggregated proteins to therapeutic targets and biomarkers[@mitochondrial][@tau_pathology].

Scope of Neurodegenerative Diseases Covered

The Entities section encompasses the following major disease categories:

Path: `entities/overview`

Introduction

The Entities section serves as a comprehensive reference for key biological entities, drug targets, biomarkers, and therapeutic concepts in neurodegenerative disease research. This overview provides context for navigating the 171+ entity pages in NeuroWiki, covering the molecular players, cellular components, and therapeutic interventions central to understanding Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders.

Neurodegenerative diseases share common pathological mechanisms including protein aggregation, mitochondrial dysfunction, neuroinflammation, and impaired protein homeostasis. The entities documented in this section represent the key molecular actors in these processes, spanning from disease-causing genes and aggregated proteins to therapeutic targets and biomarkers[@mitochondrial][@tau_pathology].

Scope of Neurodegenerative Diseases Covered

The Entities section encompasses the following major disease categories:

Why Entity Documentation Matters

Comprehensive documentation of biological entities serves multiple purposes:

• Understanding Disease Mechanisms: Each entity represents a piece of the mechanistic puzzle
• Identifying Therapeutic Targets: Drug development requires detailed understanding of molecular players
• Biomarker Discovery: Many entities serve as diagnostic or prognostic markers
• Genetic Risk Assessment: Gene variant interpretation guides clinical decision-making
• Research Translation: Basic science findings inform clinical applications

Entity Categories

Proteins & Peptides

The protein entities in NeuroWiki encompass the hallmark pathological proteins, their precursors, processing enzymes, and associated regulatory molecules.

Amyloid-Related Proteins:

• [Amyloid Precursor Protein (APP)](/entities/app-protein) — The transmembrane precursor protein that gives rise to amyloid beta through sequential proteolytic cleavage
• [Amyloid Beta (Aβ)](/proteins/amyloid-beta) — The 38-43 amino acid peptide that forms extracellular plaques in AD
• [BACE1](/entities/bace1) — Beta-secretase, the rate-limiting enzyme that initiates Aβ production

• [Tau Protein](/proteins/tau) — The microtubule-stabilizing protein that forms neurofibrillary tangles in AD
• [GSK3B](/genes/gsk3b) — Glyogen synthase kinase 3 beta, a major tau kinase
• [CDK5](/genes/cdk5) — Cyclin-dependent kinase 5, implicated in tau phosphorylation

• [Alpha-Synuclein](/proteins/alpha-synuclein) — The presynaptic protein that forms Lewy bodies in PD and DLB

• [BDNF](/entities/bdnf) — Brain-derived neurotrophic factor, critical for neuronal survival and plasticity
• [GDNF](/entities/gdnf) — Glial cell line-derived neurotrophic factor, supports dopaminergic neurons

• [VMAT2](/genes/vmat2) — Vesicular monoamine transporter 2, packages dopamine into synaptic vesicles
• [Dopamine Transporter](/entities/dopamine-transporter) — Regulates synaptic dopamine clearance

Genes & Genetic Factors

Genetic factors play a critical role in both familial and sporadic forms of neurodegenerative diseases.

Disease-Causing Genes:

• [APOE](/proteins/apoe) — Apolipoprotein E, the strongest genetic risk factor for late-onset AD
• [C9orf72](/entities/c9orf72) — Hexanucleotide repeat expansion causes ALS/FTD
• [GBA](/entities/gba) — Glucocerebrosidase, major risk factor for PD
• [LRRK2](/entities/lrrk2) — Leucine-rich repeat kinase 2, common genetic cause of familial PD
• [SNCA](/genes/snca) — Alpha-synuclein gene, first gene linked to familial PD
• [PSEN1](/entities/psen1) — Presenilin 1, causal gene for early-onset familial AD
• [PSEN2](/entities/psen2) — Presenilin 2, another AD-causing presenilin gene

• [BIN1](/genes/bin1) — Bridging integrator 1, second-most significant AD risk locus
• [CLU](/genes/clu) — Clusterin, complement regulator linked to AD risk
• [PICALM](/genes/picalm) — Phosphatidylinositol binding clathrin assembly protein, affects APP trafficking

• [TREM2](/proteins/trem2) — Triggering receptor expressed on myeloid cells 2, rare variants increase AD risk 3-4x
• [PLD3](/genes/pld3) — Phospholipase D3, rare variant linked to AD

Cell Types & Cellular Components

Understanding the cellular context of neurodegeneration requires detailed knowledge of the affected cell types and their specialized structures.

Neuronal Cell Types:

• [Dopaminergic Neurons](/entities/dopaminergic-neurons) — The vulnerable neurons in the substantia nigra pars compacta that degenerate in PD
• [Cholinergic Neurons](/cell-types/cholinergic-neurons) — Basal forebrain neurons lost early in AD
• [Cortical Neurons](/cell-types/cortical-neurons) — Pyramidal neurons affected in AD and FTD

• [Astrocytes](/entities/astrocytes) — Support neurons, maintain homeostasis, become reactive in neurodegeneration
• [Microglia](/entities/microglia) — Resident immune cells, drive neuroinflammation[@microglia2023]
• [Oligodendrocytes](/entities/oligodendrocytes) — Myelin-producing cells affected in MSA

• [Blood-Brain Barrier](/entities/blood-brain-barrier) — Protective barrier whose dysfunction contributes to disease
• [Synapse](/entities/synapse) — The site of neuronal communication, early target in neurodegeneration
• [Mitochondria](/entities/mitochondria) — Cellular powerhouses whose dysfunction is central to many neurodegenerative processes[@mitochondrial]

Biomarkers

Biomarkers enable early diagnosis, disease staging, and monitoring of therapeutic response.

Fluid Biomarkers:

• [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light-chain-nfl) — Axonal damage marker elevated in blood and CSF
• [Tau](/proteins/tau) — Total and phosphorylated tau in CSF reflect neuronal injury
• [Alpha-Synuclein](/proteins/alpha-synuclein) — Seeded aggregation assays detect pathological forms

• [Amyloid PET](/entities/amyloid-pet) — Detects cerebral amyloid angiopathy and plaques
• [FDG PET](/entities/fdg-pet) — Measures cerebral glucose metabolism
• [Tau PET](/entities/tau-pet) — Visualizes neurofibrillary tangles in vivo

Drugs & Therapies

The therapeutic landscape for neurodegenerative diseases includes approved treatments and investigational agents.

Approved Treatments:

• [Donepezil](/entities/donepezil) — Acetylcholinesterase inhibitor for AD
• [Memantine](/therapeutics/memantine) — NMDA receptor antagonist for moderate-to-severe AD
• [Levodopa](/therapeutics/levodopa) — Dopamine precursor for PD motor symptoms

• [Aducanumab](/entities/aduhelm) — Anti-amyloid antibody with FDA approval (Aduhelm)
• [Lecanemab](/entities/lecanemab) — Anti-amyloid antibody (Leqembi), full FDA approval
• [Donanemab](/entities/donanemab) — Anti-amyloid antibody (Kisunla), full FDA approval

• [BACE1 Inhibitors](/entities/bace1-inhibitors-alzheimers) — Attempted to block Aβ production
• [Tau Immunotherapy](/therapeutics/tau-immunotherapy) — Active and passive immunization against tau

Key Pathways Represented

1. Amyloid Cascade

The amyloid cascade hypothesis posits that Aβ accumulation initiates a cascade leading to tau pathology, synaptic loss, and cognitive decline. Key entities in this pathway include:

• APP undergoes sequential cleavage by [BACE1](/entities/bace1) and γ-secretase to produce Aβ
• Aβ42 (42 amino acid isoform) aggregates more readily than Aβ40
• Oligomeric Aβ species are thought to be the most neurotoxic form
• Therapeutic approaches include reducing production (BACE inhibitors), enhancing clearance (immunotherapy), and preventing aggregation (small molecules)

2. Tau Pathology

Tau protein forms neurofibrillary tangles (NFTs) that correlate with clinical severity better than amyloid burden[@tau_pathology]:

• Hyperphosphorylation of tau reduces its microtubule-binding capacity
• Tau seeds can propagate between neurons in a prion-like manner
• Tau pathology spreads in a predictable pattern (Braak stages)
• Multiple kinases (GSK3B, CDK5) and phosphatases (PP2A) regulate tau phosphorylation

3. Alpha-Synucleinopathy

Alpha-synuclein aggregation characterizes PD, DLB, and MSA[@alpha_synuclein]:

• Lewy bodies are cytoplasmic inclusions rich in aggregated α-synuclein
• The protein adopts β-sheet conformations that seed further aggregation
• Pathological α-synuclein can spread between connected brain regions
• Mutations (A53T, A30P, E46K) cause familial forms of PD

4. Neuroinflammation

Chronic neuroinflammation is a hallmark of all neurodegenerative diseases[@neuroinflammation]:

• [Microglia](/entities/microglia) become persistently activated, producing pro-inflammatory cytokines
• The [Complement System](/entities/complement-system) contributes to synaptic elimination
• TREM2 on microglia senses Aβ and triggers protective responses
• Anti-inflammatory therapies have not yet demonstrated clinical benefit

5. Mitochondrial Dysfunction

Mitochondrial impairment is central to neurodegeneration[@mitochondrial]:

• PINK1/Parkin pathway detects and eliminates damaged mitochondria through mitophagy
• Complex I deficiency is well-documented in PD substantia nigra
• Mitochondrial DNA mutations accumulate in neurons with age
• Energy failure leads to calcium dysregulation and excitotoxicity

6. Protein Homeostasis

The [UPS](/mechanisms/ubiquitin-proteasome-system) and autophagy-lysosome system maintain proteostasis[@protein_homeostasis]:

• Ubiquitin tags proteins for degradation by the proteasome
• Autophagy removes larger aggregates and damaged organelles
• chaperone proteins assist folding and prevent aggregation
• Impairment leads to accumulation of toxic protein aggregates

Molecular Interaction Networks

APP Processing Network

Alpha-Synuclein Lifecycle

Shared Disease Mechanisms

Neurodegenerative diseases, despite their clinical diversity, share fundamental biological processes that represent key therapeutic targets.

Proteostasis Failure

The ability to maintain proper protein folding and clearance is compromised in all neurodegenerative diseases:

Protein Misfolding: Genetic mutations, environmental stressors, and aging can cause proteins to adopt abnormal conformations. Misfolded proteins expose hydrophobic regions that promote aggregation into oligomers, fibrils, and eventually insoluble inclusions.

Impaired Clearance: The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway are both affected in neurodegeneration. Proteasome activity declines with age, and autophagy becomes less efficient. Lysosomal function is compromised by lipid accumulation and cellular stress.

Seeded Aggregation: Pathological proteins can act as "seeds" that template the misfolding of normal proteins, creating a prion-like propagation. This explains the spread of pathology through connected brain regions[@alpha_synuclein].

Cellular Energy Crisis

Neurons have exceptionally high energy demands but limited capacity for glycolysis, making them vulnerable to mitochondrial dysfunction:

Oxidative Phosphorylation Defects: Complex I deficiency is well-documented in PD, and similar impairments occur in AD. Decreased ATP production compromises ion gradient maintenance, neurotransmitter recycling, and cellular homeostasis.

Calcium Dysregulation: Mitochondrial dysfunction leads to impaired calcium buffering. Elevated cytosolic calcium activates destructive pathways including proteases, phosphatases, and apoptotic cascades.

Reactive Oxygen Species: Electron leakage from damaged mitochondria generates superoxide and other ROS. Neurons are particularly vulnerable because of high lipid content and limited antioxidant capacity.

See: [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)

Neuroinflammatory Cascade

Chronic neuroinflammation is both a cause and consequence of neurodegeneration[@neuroinflammation]:

Microglial Activation: Resting microglia become activated by pathological proteins (Aβ, α-synuclein, tau), damage-associated molecular patterns (DAMPs), and complement components. Once activated, they produce pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that create a toxic environment.

Complement Activation: The complement system tags synapses for elimination by microglia. Excessive complement activation contributes to synaptic loss, which correlates best with cognitive decline.

Peripheral Immune System: Blood-derived monocytes and T cells can enter the CNS in neurodegeneration. The blood-brain barrier becomes more permeable, allowing peripheral immune cells to contribute to pathology.

Synaptic Failure

Synapse loss is the strongest correlate of cognitive decline:

Early Vulnerability: Synapses are early targets in both AD and PD. Synaptic proteins are reduced in vulnerable brain regions before neuron loss is evident.

Excitotoxicity: Excessive glutamate receptor activation leads to calcium influx and downstream damage. NMDA receptor overactivation is particularly harmful.

Protein Misfolding at Synapses: Aβ oligomers bind directly to synapses, impairing function. α-Synuclein aggregates at presynaptic terminals, disrupting neurotransmitter release.

Axonal Transport Defects

Long neurons require efficient transport systems:

Microtubule Disruption: Tau pathology disrupts microtubule stability, impairing transport of organelles, proteins, and RNA between cell body and synapse.

Motor Protein Dysfunction: Kinesins and dyneins that walk along microtubules are affected by multiple disease mechanisms. Transport deficits precede neurodegeneration.

Energy-Dependent Process: Axonal transport requires ATP, so mitochondrial dysfunction directly impairs this critical function.

Therapeutic Target Categories

Disease-Modifying Targets

| Target Category | Key Entities | Therapeutic Approach |
|-----------------|--------------|---------------------|
| Amyloid Reduction | BACE1, APP, γ-secretase | Small molecule inhibitors |
| Amyloid Removal | Aβ peptides | Active/passive immunotherapy |
| Tau Modification | GSK3B, CDK5, PP2A | Kinase inhibitors, phosphatase activators |
| Tau Clearance | Tau protein | Immunotherapy |
| α-Synuclein | SNCA, GBA | Immunotherapy, gene silencing |
| Neuroinflammation | TREM2, CD33, complement | Antibody therapy, small molecules |
| Mitochondrial Function | PINK1, Parkin, TFAM | Gene therapy, small molecules |
| Protein Homeostasis | UPS, autophagy machinery | Enhancers of clearance |

Symptomatic Targets

| Symptom | Target | Therapeutic Agent |
|---------|--------|-------------------|
| Cognitive Decline | Acetylcholinesterase | Donepezil, Rivastigmine, Galantamine |
| Cognitive Decline | NMDA Receptor | Memantine |
| Motor Symptoms | Dopamine Receptor | Pramipexole, Ropinirole |
| Motor Symptoms | MAO-B | Selegiline, Rasagiline |
| Motor Fluctuations | COMT | Entacapone, Tolcapone |
| Neuropsychiatric | 5-HT2A | Pimavanserin |

Emerging Concepts

1. Protein Co-Pathology

Recent research reveals that neurodegenerative diseases commonly involve multiple protein aggregates:

• Many AD brains contain α-synuclein (Lewy bodies) in addition to amyloid and tau
• Tau pathology is frequently found in PD brains (tauopathy co-occurrence)
• The presence of multiple pathologies correlates with more severe clinical presentation

2. Genetic Risk Architecture

Genome-wide association studies (GWAS) have identified numerous risk loci:

• Over 40 AD risk loci identified (APOE, CLU, PICALM, BIN1, SORL1, etc.)
• Over 20 PD risk loci identified (GBA, LRRK2, SNCA, PARK16, etc.)
• Many risk genes converge on common biological pathways (endocytosis, immune response)

3. Epigenetic Mechanisms

Environmental factors influence disease through epigenetic modifications:

• DNA methylation patterns change with age and disease
• Histone modifications affect expression of neurodegeneration-related genes
• Non-coding RNAs (miRNAs, lncRNAs) regulate gene expression post-transcriptionally

4. Cellular Senescence

Cellular senescence contributes to neurodegeneration:

• Senescent neurons and glia accumulate with age
• Senescence-associated secretory phenotype (SASP) drives inflammation
• Senolytics are being explored as potential therapeutics

Navigation and Resources

• All Entities (A-Z): [Entities Index](/entities) — Complete alphabetical listing
• Genes: [Genes Section](/genes) — Focused gene pages with variant information
• Proteins: [Proteins Section](/proteins) — Detailed protein structure and function
• Biomarkers: [Biomarkers Section](/biomarkers) — Diagnostic and prognostic markers
• Mechanisms: [Mechanisms Section](/mechanisms) — Process pathways and diagrams

Statistics

| Category | Count | Reference |
|----------|-------|-----------|
| Total Entity Pages | 171+ | |
| Protein Entities | ~60 | |
| Gene Entities | ~40 | |
| Drug/Treatment Entities | ~35 | |
| Cell Type/Component Entities | ~20 | |
| Other Entities | ~16 | |

Cross-Linking and Connectivity

The entities in this section are interconnected through multiple pathways:

• Gene-Protein-Disease Triangles: Each disease-linked gene encodes a protein involved in disease mechanisms
• Pathway Membership: Many entities participate in multiple overlapping pathways
• Therapeutic Targeting: Drug entities modulate the function of disease-related proteins
• Biomarker Relationships: Many biomarkers directly measure disease-related proteins or their fragments

Entity Relationship Examples

APOE → Amyloid → Alzheimer's Disease

• [APOE](/proteins/apoe) (gene/protein) affects Aβ clearance and aggregation
• [Amyloid Beta](/proteins/amyloid-beta) is the pathological protein
• [Alzheimer's Disease](/diseases/alzheimers-disease) is the clinical phenotype

• [GBA](/entities/gba) mutations increase PD risk 5-10x
• [Alpha-Synuclein](/proteins/alpha-synuclein) aggregation is enhanced
• [Parkinson's Disease](/diseases/parkinsons-disease) manifests with Lewy bodies

• [LRRK2](/entities/lrrk2) mutations cause familial PD
• Pathogenic LRRK2 affects tau phosphorylation
• Leads to dopaminergic neuron degeneration

Entity Documentation Standards

All entity pages in NeuroWiki follow consistent documentation standards:

Required Elements

Quality Benchmarks

• Minimum Length: 500 words for standalone entity pages
• References: At least 5 PubMed references for key entities
• Diagrams: Mermaid.js flowcharts for pathway entities
• Cross-Links: Minimum 10 internal links to other NeuroWiki pages

Future Directions

The Entities section continues to evolve with emerging research:

Expanding Coverage

• Epigenetic Regulators: Adding pages for DNA methyltransferases, histone modifiers
• Non-Coding RNAs: miRNAs and lncRNAs implicated in neurodegeneration
• Metabolomic Entities: Key metabolites and metabolic pathways
• Single-Cell Markers: Cell type-specific markers for finer categorization

Integration with Other Sections

• Mechanisms: Deeper cross-linking to pathway documentation
• Clinical: Connection to clinical trials and therapeutic approaches
• Research: Linking to researcher profiles and institutional resources

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Mechanisms Overview](/mechanisms)
• [Genes Section](/genes)
• [Proteins Section](/proteins)
• [Biomarkers Section](/biomarkers)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
• [Allen Human Brain Atlas](https://brain-map.org/)
• [GWAS Catalog](https://www.ebi.ac.uk/gwas/)

Summary Statistics

• Total Pages: 171+ entity pages in this section
• Last Updated: This section is actively maintained and expanded
• Coverage: Comprehensive documentation of molecular players in neurodegeneration
• Quality: All entity pages include proper references with hyperlinked DOIs and PMIDs

References